Starving cancer cells: could cholesterol drugs slow pancreatic tumors?
NCT ID NCT04862260
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop pancreatic cancer growth. Cancer cells need lots of cholesterol to grow, and this approach aims to starve them. The trial includes 3 adults with advanced or metastatic pancreatic cancer who have not yet had treatment. The main goal is to check if the drug combination is safe and feasible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Québec-Université Laval
Québec, Quebec, G1R 2J6, Canada
-
CHUM
Montreal, Quebec, H2X 0A9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new drug combo shrink Hard-to-Treat tumors?